Prof Dr Giuseppe Curigliano, a medical oncologist at the European Institute of...
At ASCO, Prof Jeffrey Weber presented the 3-year update of the KEYNOTE-942...
Study 22 was a phase I/II trial evaluating different immune checkpoint...
Dr Elisa Agostinetto and Prof Dr Laurence Buisseret, both medical oncologists...
During the 2024 ASCO GU meeting earlier this year, the CheckMate 8HW study...
Previously, the phase III EMERALD-1 trial showed that a regimen combining...
In the pivotal, phase III CheckMate 816 study, neoadjuvant nivolumab in...
Based on the results of CheckMate-067 and RELATIVITY-047, the combination of...
In recent years, several studies have evaluated the optimal treatment sequence...
Over the last decades, therapeutic advances for patients with limited-stage...